Hot Longevity Mandate: Chinese Pharmaceutical Company

17 Aug

The firm is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, the firm has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. The firm has received three NDA approvals, including two in mainland China and one in Taiwan, and multiple late-stage candidates are in pivotal trials or registrational stages. The firm’s vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide. The company is currently seeking in-licensing, out-licensing and partnership opportunities globally.

The firm is particularly interested in first-in-class, truly innovative oncology assets from pre-clinical to market except for CAR-T therapy and gene therapy. The firm is interested in opportunities for both greater China as well as global market.

The firm’s team is flexible and is open to working with all different kinds of management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: